IGI Laboratories, Inc. Announces First ANDA Submission Of 2015

IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-three. Jason Grenfell-Gardner, President and CEO of the Company, commented, "On March 2, 2015, we committed to file at least twenty ANDAs in 2015.  We believe the ANDA filed today has an addressable market of $20 million based on January 2015 data from IMS Health.  We believe our current pipeline of submissions, exclusive of partnered submissions, pending approval by the FDA now has a combined addressable market of over $623 million based on January 2015 data from IMS Health." About IGI Laboratories, Inc. IGI Laboratories is a specialty generic pharmaceutical company.  Our mission is to be a leading player in the specialty generic prescription drug market. Forward-Looking Statements This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this See full press release